Taiwanese Journal of Obstetrics & Gynecology最新文献

英文中文

Surgical approach for fertility-sparing adenomyosis treatment 保留生育能力的子宫腺肌症手术治疗方法

IF 2.2 4区医学 Q2 OBSTETRICS & GYNECOLOGY

Taiwanese Journal of Obstetrics & Gynecology

Pub Date : 2026-01-01 DOI: 10.1016/j.tjog.2025.11.003

Szu-Ting Yang, Chia-Hao Liu, Peng-Hui Wang

引用次数: 0

Prenatal diagnosis and genetic counseling of a rare maternally inherited 2q12.2q13 duplication in a Chinese family 一个中国家庭罕见母系遗传2q12.2q13重复的产前诊断和遗传咨询

IF 2.2 4区医学 Q2 OBSTETRICS & GYNECOLOGY

Taiwanese Journal of Obstetrics & Gynecology

Pub Date : 2026-01-01 DOI: 10.1016/j.tjog.2025.05.022

Bo Zhang , Haiyang Hu , Bo Wang , Huili Luo

引用次数: 0

Mirvetuximab soravtansine-Gynx (MIRV) for treating platinum-resistant recurrent ovarian cancer Mirvetuximab soravtansine- gyx （MIRV）治疗铂耐药复发性卵巢癌

IF 2.2 4区医学 Q2 OBSTETRICS & GYNECOLOGY

Taiwanese Journal of Obstetrics & Gynecology

Pub Date : 2026-01-01 DOI: 10.1016/j.tjog.2025.11.019

Peng-Hui Wang , Che-Wei Chang , Szu-Ting Yang , Wen-Hsun Chang

Mirvetuximab soravtansine (MIRV), an anti-folate receptor 1/alpha (FRα, FOLR1) antibody-drug conjugate (ADC) with a companion diagnostic immunohistochemical (IHC) biomarker using VENTANA FOLR1 assay represents a precisely targeted chemotherapy for treating platinum-resistant recurrent epithelial ovarian cancer (PR-rEOC) patients with overexpression of FRα and possibly for platinum-sensitive rEOC (PS-rEOC) patients, regardless of status of FRα expression. The global phase III randomized clinical trial (RCT, MIRASOL) enrolling 453 highly FRα expressed PR-rEOC patients demonstrated that MIRV treatment provided statistically significant improvements in clinical outcomes compared to investigator’s choice of chemotherapy (ICC), which included not only the progression free-survival (median PFS 5.6 months vs. 4.0 months, hazard ratio [HR] 0.65) but also the overall survival (median OS 16.5 months vs. 12.8 months, HR 0.67). Additionally, overall response rate (ORR) was significantly higher in MIRV treatment (42.3 % vs. 15.9 %). Moreover, the severe adverse events (AEs) and treatment-related AEs (TRAEs)-associated discontinuation in MIRV group were dramatically fewer (41.7 % vs. 54.1 %) and lower (9.2 % vs. 15.9 %), respectively compared to ICC group. These findings suggest that the treatment of choice may be the utilizing MIRV as the front-line for treating PR-rEOC patients if FRα expression of Pr-rEOC patients is high. Finally, any-grade ocular adverse events (OAEs) are particularly common in patients during MIRV treatment, arising in 125 (57 %); grade ≥3 in 34 (16 %), most frequently, blurred vision (18 [8 %]), keratopathy (21 [10 %]), cataract (11 [5 %]), and dry eye (8 [4 %]); however, fortunately, over 90 % with OAEs had either full resolution or documented final grade 1 or better. The current review also discusses OAE, based on its high incidence, frequent cause responsible to dose reduction and delaying therapy with impacting 11–35 % of patients and of the most importance, relative unfamiliarity to most gynecological oncologists in the routine clinical practice.

Mirvetuximab soravtansine （MIRV）是一种抗叶酸受体1/ α (FRα, FOLR1)抗体-药物偶联物（ADC），使用VENTANA FOLR1检测伴有诊断性免疫组织化学（IHC）生物标志物，代表了一种精确靶向化疗，用于治疗FRα过表达的铂耐药复发性上皮性卵巢癌（PR-rEOC）患者，也可能用于铂敏感的rEOC （psreoc）患者，无论FRα表达状态如何。纳入453名高FRα表达PR-rEOC患者的全球III期随机临床试验（RCT， MIRASOL）表明，与研究者选择的化疗（ICC）相比，MIRV治疗在临床结果方面提供了统计学上显著的改善，其中不仅包括无进展生存期（中位PFS 5.6个月对4.0个月，风险比[HR] 0.65），而且包括总生存期（中位OS 16.5个月对12.8个月，HR 0.67）。此外，MIRV治疗的总缓解率（ORR）显著更高（42.3%对15.9%）。此外，与ICC组相比，MIRV组的严重不良事件（ae）和治疗相关ae （TRAEs）相关的停药率分别显著减少（41.7%对54.1%）和更低（9.2%对15.9%）。这些发现提示，如果PR-rEOC患者FRα表达较高，可以选择MIRV作为一线治疗PR-rEOC患者。最后，任何级别的眼部不良事件（oae）在MIRV治疗期间的患者中特别常见，发生125例（57%）；34例(16%)≥3级，最常见的是视力模糊（18例[8%]）、角膜病变（21例[10%]）、白内障（11例[5%]）和干眼（8例[4%]）；然而，幸运的是，超过90%的oae患者要么完全解决了问题，要么最终记录为1级或更高。本综述还讨论了OAE，基于其发病率高，导致剂量减少和延迟治疗的常见原因，影响11 - 35%的患者，最重要的是，大多数妇科肿瘤学家在常规临床实践中相对不熟悉。

{"title":"Mirvetuximab soravtansine-Gynx (MIRV) for treating platinum-resistant recurrent ovarian cancer","authors":"Peng-Hui Wang , Che-Wei Chang , Szu-Ting Yang , Wen-Hsun Chang","doi":"10.1016/j.tjog.2025.11.019","DOIUrl":"10.1016/j.tjog.2025.11.019","url":null,"abstract":"<div><div>Mirvetuximab soravtansine (MIRV), an anti-folate receptor 1/alpha (FRα, FOLR1) antibody-drug conjugate (ADC) with a companion diagnostic immunohistochemical (IHC) biomarker using VENTANA FOLR1 assay represents a precisely targeted chemotherapy for treating platinum-resistant recurrent epithelial ovarian cancer (PR-rEOC) patients with overexpression of FRα and possibly for platinum-sensitive rEOC (PS-rEOC) patients, regardless of status of FRα expression. The global phase III randomized clinical trial (RCT, MIRASOL) enrolling 453 highly FRα expressed PR-rEOC patients demonstrated that MIRV treatment provided statistically significant improvements in clinical outcomes compared to investigator’s choice of chemotherapy (ICC), which included not only the progression free-survival (median PFS 5.6 months <em>vs.</em> 4.0 months, hazard ratio [HR] 0.65) but also the overall survival (median OS 16.5 months <em>vs.</em> 12.8 months, HR 0.67). Additionally, overall response rate (ORR) was significantly higher in MIRV treatment (42.3 % <em>vs.</em> 15.9 %). Moreover, the severe adverse events (AEs) and treatment-related AEs (TRAEs)-associated discontinuation in MIRV group were dramatically fewer (41.7 % vs. 54.1 %) and lower (9.2 % vs. 15.9 %), respectively compared to ICC group. These findings suggest that the treatment of choice may be the utilizing MIRV as the front-line for treating PR-rEOC patients if FRα expression of Pr-rEOC patients is high. Finally, any-grade ocular adverse events (OAEs) are particularly common in patients during MIRV treatment, arising in 125 (57 %); grade ≥3 in 34 (16 %), most frequently, blurred vision (18 [8 %]), keratopathy (21 [10 %]), cataract (11 [5 %]), and dry eye (8 [4 %]); however, fortunately, over 90 % with OAEs had either full resolution or documented final grade 1 or better. The current review also discusses OAE, based on its high incidence, frequent cause responsible to dose reduction and delaying therapy with impacting 11–35 % of patients and of the most importance, relative unfamiliarity to most gynecological oncologists in the routine clinical practice.</div></div>","PeriodicalId":49449,"journal":{"name":"Taiwanese Journal of Obstetrics & Gynecology","volume":"65 1","pages":"Pages 15-21"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146057482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-level mosaicism for 45,X in 45,X/46,XX at amniocentesis in a pregnancy associated with perinatal progressive decrease of the 45,X cell line, a phenotypically normal child and the karyotype of 46,XX in the peripheral blood at age 7½ months 妊娠期羊膜穿刺术中45，X,X/46，XX高水平嵌合与围产期45，X细胞系进行性减少有关，表型正常的儿童，7½月龄时外周血核型46，XX

IF 2.2 4区医学 Q2 OBSTETRICS & GYNECOLOGY

Taiwanese Journal of Obstetrics & Gynecology

Pub Date : 2026-01-01 DOI: 10.1016/j.tjog.2025.11.011

Chih-Ping Chen

引用次数: 0

Instruction for Authors 作者须知

IF 2.2 4区医学 Q2 OBSTETRICS & GYNECOLOGY

Taiwanese Journal of Obstetrics & Gynecology

Pub Date : 2026-01-01 DOI: 10.1016/S1028-4559(26)00065-3

引用次数: 0

Low-level mosaicism for 45,X in 45,X/46,XX at amniocentesis associated with perinatal decrease of the 45,X cell line and a favorable fetal outcome in a pregnancy 在羊膜穿刺术中，45、X、X/46、XX的低水平嵌合与45、X细胞系的围产期减少和妊娠中有利的胎儿结局相关

IF 2.2 4区医学 Q2 OBSTETRICS & GYNECOLOGY

Taiwanese Journal of Obstetrics & Gynecology

Pub Date : 2026-01-01 DOI: 10.1016/j.tjog.2025.11.010

Chih-Ping Chen

引用次数: 0

Massive retained products of conception with arteriovenous fistula successfully treated with arterial balloon occlusion and laparoscopic hysterectomy 经动脉球囊封堵及腹腔镜子宫切除术成功治疗孕腔内大量残留动静脉瘘

IF 2.2 4区医学 Q2 OBSTETRICS & GYNECOLOGY

Taiwanese Journal of Obstetrics & Gynecology

Pub Date : 2026-01-01 DOI: 10.1016/j.tjog.2025.09.023

Shizuha Iwaizumi , Ryoko Asano , Shinjiro Aso , Sayako Nakagawa , Emi Onuma , Shin Saito , Tae Mogami , Hideya Sakakibara

Objective

We report the case of retained products of conception (RPOC) with massive uterine arteriovenous fistula (AVF).

Case report

A 42-year-old woman was referred to our hospital for having abnormal pregnancy at 9 weeks. Ultrasonography showed a deformed gestational sac. Serum hCG levels were initially markedly elevated but demonstrated a progressive decline over time. At 20 weeks gestation, a uterine mass grew with an abundant blood flow to replace the myometrium. The 3-dimensional blood vessel image constructed from the contrast enhanced CT showed a formation of massive AVF in the uterine mass. In consideration of the high risk of intraoperative hemorrhage, bilateral internal iliac artery balloon occlusion was strategically utilized as an adjunct, facilitating the execution of a minimally invasive total laparoscopic hysterectomy.

Conclusion

It is important to evaluate the vessel image and select appropriate treatment considering the risk of bleeding.

目的报告大量子宫动静脉瘘（AVF）并发妊娠产物保留（RPOC）病例。病例报告一名42岁妇女因9周异常妊娠转诊至我院。超声显示妊娠囊畸形。血清hCG水平最初明显升高，但随着时间的推移逐渐下降。妊娠20周时，子宫肿块生长，血流充足，取代子宫肌层。增强CT三维血管图像显示子宫肿块内形成大量AVF。考虑到术中出血的高风险，我们策略性地利用双侧髂内动脉球囊闭塞作为辅助手段，方便微创腹腔镜全子宫切除术的实施。结论考虑出血风险，评估血管图像，选择合适的治疗方法是重要的。

{"title":"Massive retained products of conception with arteriovenous fistula successfully treated with arterial balloon occlusion and laparoscopic hysterectomy","authors":"Shizuha Iwaizumi , Ryoko Asano , Shinjiro Aso , Sayako Nakagawa , Emi Onuma , Shin Saito , Tae Mogami , Hideya Sakakibara","doi":"10.1016/j.tjog.2025.09.023","DOIUrl":"10.1016/j.tjog.2025.09.023","url":null,"abstract":"<div><h3>Objective</h3><div>We report the case of retained products of conception (RPOC) with massive uterine arteriovenous fistula (AVF).</div></div><div><h3>Case report</h3><div>A 42-year-old woman was referred to our hospital for having abnormal pregnancy at 9 weeks. Ultrasonography showed a deformed gestational sac. Serum hCG levels were initially markedly elevated but demonstrated a progressive decline over time. At 20 weeks gestation, a uterine mass grew with an abundant blood flow to replace the myometrium. The 3-dimensional blood vessel image constructed from the contrast enhanced CT showed a formation of massive AVF in the uterine mass. In consideration of the high risk of intraoperative hemorrhage, bilateral internal iliac artery balloon occlusion was strategically utilized as an adjunct, facilitating the execution of a minimally invasive total laparoscopic hysterectomy.</div></div><div><h3>Conclusion</h3><div>It is important to evaluate the vessel image and select appropriate treatment considering the risk of bleeding.</div></div>","PeriodicalId":49449,"journal":{"name":"Taiwanese Journal of Obstetrics & Gynecology","volume":"65 1","pages":"Pages 110-113"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146057471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endometrial cancer: Hypothesis of WANG immunohistochemistry-based molecular classification of endometrial cancer (WANG-EC-Mol) 基于WANG免疫组织化学的子宫内膜癌分子分类（WANG- ec - mol）

IF 2.2 4区医学 Q2 OBSTETRICS & GYNECOLOGY

Taiwanese Journal of Obstetrics & Gynecology

Pub Date : 2026-01-01 DOI: 10.1016/j.tjog.2025.10.002

Peng-Hui Wang

引用次数: 0

Healthcare provider bias in cancer treatment decisions for elderly patients 老年患者癌症治疗决策中的医疗保健提供者偏倚

IF 2.2 4区医学 Q2 OBSTETRICS & GYNECOLOGY

Taiwanese Journal of Obstetrics & Gynecology

Pub Date : 2026-01-01 DOI: 10.1016/j.tjog.2025.11.004

Hikaru Imatake, Mana Taki, Koji Yamanoi, Ryusuke Murakami, Ken Yamaguchi, Junzo Hamanishi, Masaki Mandai

Objective

The global population of elderly people is increasing, even in Japan. As a result, the number of elderly people requiring cancer treatment is also increasing, and it is necessary to assess the tolerability of elderly people. In recent years, the Comprehensive Geriatric Assessment (CGA), an objective assessment tool for evaluating elderly patients, has been introduced, but it is not yet common. In this study, we compared elderly cancer patients who were divided into standard treatment and non-standard treatment groups due to the subjective bias of healthcare providers and examined what was being subjectively selected without being conscious of it.

Materials and methods

We retrospectively reviewed cases of patients aged 75 and older diagnosed with endometrial cancer, cervical cancer, or ovarian cancer at our hospital between April 1, 2018, and March 31, 2022, who surgery was deemed the standard treatment. Data on age, body mass index (BMI), performance status (PS), pre-treatment blood hemoglobin (Hb), albumin (Alb), creatinine (Cre), cancer antigen 125 (CA 125) levels, use of oral medications (antihypertensives, diabetes medications, anticoagulants, antiplatelet agents, diuretics), and history of malignancies were collected from electronic medical records. Patients who underwent standard treatment (standard treatment group) were compared to those who had changes in surgical content or received non-surgical treatments (non-standard treatment group).

Results

In standard treatment group, age, nutritional status (body mass index, albumin and hemoglobin levels) and physical functions (performance status) were significantly higher, which are the main evaluation factors of CGA.

Conclusion

These results suggest that the bias of healthcare providers to some extent reflects the CGA.

全球老年人口正在增加，即使在日本也是如此。因此，需要癌症治疗的老年人数量也在不断增加，有必要对老年人的耐受性进行评估。近年来，一种评价老年患者的客观评估工具——综合老年评估（Comprehensive Geriatric Assessment， CGA）被引入，但尚未普及。在本研究中，我们比较了由于医疗服务提供者的主观偏见而被分为标准治疗组和非标准治疗组的老年癌症患者，并检查了在无意识的情况下主观选择了什么。材料和方法回顾性分析2018年4月1日至2022年3月31日期间在我院诊断为子宫内膜癌、宫颈癌或卵巢癌的75岁及以上患者，手术被视为标准治疗方法。从电子病历中收集年龄、体重指数（BMI）、体能状态（PS）、治疗前血红蛋白（Hb）、白蛋白（Alb）、肌酐（Cre）、癌症抗原125 （CA 125）水平、口服药物（降压药、糖尿病药物、抗凝剂、抗血小板药、利尿剂）使用情况和恶性肿瘤病史等数据。将接受标准治疗的患者（标准治疗组）与手术内容改变或接受非手术治疗的患者（非标准治疗组）进行比较。结果标准治疗组的年龄、营养状况（体重指数、白蛋白和血红蛋白水平）和身体机能（工作状态）显著高于标准治疗组，这是CGA的主要评价因素。结论医疗服务提供者的偏见在一定程度上反映了CGA。

{"title":"Healthcare provider bias in cancer treatment decisions for elderly patients","authors":"Hikaru Imatake, Mana Taki, Koji Yamanoi, Ryusuke Murakami, Ken Yamaguchi, Junzo Hamanishi, Masaki Mandai","doi":"10.1016/j.tjog.2025.11.004","DOIUrl":"10.1016/j.tjog.2025.11.004","url":null,"abstract":"<div><h3>Objective</h3><div>The global population of elderly people is increasing, even in Japan. As a result, the number of elderly people requiring cancer treatment is also increasing, and it is necessary to assess the tolerability of elderly people. In recent years, the Comprehensive Geriatric Assessment (CGA), an objective assessment tool for evaluating elderly patients, has been introduced, but it is not yet common. In this study, we compared elderly cancer patients who were divided into standard treatment and non-standard treatment groups due to the subjective bias of healthcare providers and examined what was being subjectively selected without being conscious of it.</div></div><div><h3>Materials and methods</h3><div>We retrospectively reviewed cases of patients aged 75 and older diagnosed with endometrial cancer, cervical cancer, or ovarian cancer at our hospital between April 1, 2018, and March 31, 2022, who surgery was deemed the standard treatment. Data on age, body mass index (BMI), performance status (PS), pre-treatment blood hemoglobin (Hb), albumin (Alb), creatinine (Cre), cancer antigen 125 (CA 125) levels, use of oral medications (antihypertensives, diabetes medications, anticoagulants, antiplatelet agents, diuretics), and history of malignancies were collected from electronic medical records. Patients who underwent standard treatment (standard treatment group) were compared to those who had changes in surgical content or received non-surgical treatments (non-standard treatment group).</div></div><div><h3>Results</h3><div>In standard treatment group, age, nutritional status (body mass index, albumin and hemoglobin levels) and physical functions (performance status) were significantly higher, which are the main evaluation factors of CGA.</div></div><div><h3>Conclusion</h3><div>These results suggest that the bias of healthcare providers to some extent reflects the CGA.</div></div>","PeriodicalId":49449,"journal":{"name":"Taiwanese Journal of Obstetrics & Gynecology","volume":"65 1","pages":"Pages 29-33"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146057613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Follow-up of a 1-year-and-3-month-old boy with mosaicism for 47,XXY or 47,XXY/46,XY at amniocentesis 1岁零3个月的男婴在羊膜穿刺术中出现47、XXY或47、XXY/46、XY嵌合

IF 2.2 4区医学 Q2 OBSTETRICS & GYNECOLOGY

Taiwanese Journal of Obstetrics & Gynecology

Pub Date : 2026-01-01 DOI: 10.1016/j.tjog.2025.11.013

Chih-Ping Chen

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Taiwanese Journal of Obstetrics & Gynecology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀